Research programme: anti-cancer therapeutics - Southeast TechInvetures
Alternative Names: F-10Latest Information Update: 28 Sep 2020
At a glance
- Originator Southeast TechInventures
- Class Pyrimidines; Small molecules
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in USA
- 11 Aug 2016 Research programme: anti-cancer therapeutics - Southeast TechInvetures is available for licensing as of 11 Aug 2016. http://www.setechinv.com/index.php
- 11 Aug 2016 Early research in Cancer in USA (unspecified route)